Last updated: 10 July 2024 at 4:39pm EST

Sushil Patel Ph.D. Net Worth




The estimated Net Worth of Sushil Patel is at least $934 Thousand dollars as of 9 July 2024. Mr Patel owns over 2,155 units of Replimune Inc stock worth over $229,208 and over the last 3 years he sold REPL stock worth over $704,687.

Mr D REPL stock SEC Form 4 insiders trading

Mr has made over 6 trades of the Replimune Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,155 units of REPL stock worth $36,204 on 9 July 2024.

The largest trade he's ever made was selling 20,194 units of Replimune Inc stock on 16 May 2024 worth over $130,655. On average, Mr trades about 4,343 units every 60 days since 2021. As of 9 July 2024 he still owns at least 22,103 units of Replimune Inc stock.

You can see the complete history of Mr Patel stock trades at the bottom of the page.





Mr. Sushil Patel Ph.D. biography

Sushil Patel Ph.D. is the Chief Commercial Officer at Replimune Inc.



What's Mr D's mailing address?

Sushil's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DR, REDWOOD CITY, CA, 94063.

Insiders trading at Replimune Inc

Over the last 6 years, insiders at Replimune Inc have traded over $72,652,546 worth of Replimune Inc stock and bought 2,360,000 units worth $33,565,200 . The most active insiders traders include Group, Llc Green Jeremy Red..., Capital Life Sciences Inves..., and Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of $508,649. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth $90,989.



What does Replimune Inc do?

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.



What does Replimune Inc's logo look like?

Replimune Group Inc logo

Complete history of Mr Patel stock trades at Replimune Inc and Revolution Medicines Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
9 Jul 2024 Sushil Patel
Option 2,155 $16.80 $36,204
9 Jul 2024
22,103
10 Apr 2024 Sushil Patel
Option 2,155 $16.80 $36,204
10 Apr 2024
17,855
16 May 2024 Sushil Patel
Chief Executive Officer
Sale 20,194 $6.47 $130,655
16 May 2024
212,014
13 Jun 2023 Sushil Patel
Chief Executive Officer
Sale 5,698 $24.04 $136,980
13 Jun 2023
148,873
16 May 2023 Sushil Patel
Chief Executive Officer
Sale 15,575 $18.05 $281,129
16 May 2023
154,571
16 May 2022 Sushil Patel
Chief Executive Officer
Sale 10,687 $14.59 $155,923
16 May 2022
130,146


Replimune Inc executives and stock owners

Replimune Inc executives and other stock owners filed with the SEC include: